6th ICHNO Abstract Book

page 38 6 th ICHNO Conference International Conference on innovative approaches in Head and Neck Oncology 16 – 18 March 2017 Barcelona, Spain __________________________________________________________________________________________ that PTV margins can be safely reduced if daily CBCT is possible. resource sparing regimes truly offer equivalence in efficacy and quality of life. 6th ICHNO

PO-079 Hypofractionated versus prolonged chemo-IMRT schedules in oropharyngeal carcinoma I. Boon 1 , C. Boon 1,2 , P. Nightingale 3 , J. Cashmore 1 , G. Sangha 1 , M. Hickman 1 , H. Benghiat 1 , C. Fong 1 , P. Sanghera 1,2 , A. Hartley 1,2 1 Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, United Kingdom 2 Institute of Head and Neck Studies and Education InHANSE, University of Birmingham, Birmingham, United Kingdom 3 Wolfson Computer Laboratory, Queen Elizabeth Hospital, Birmingham, United Kingdom Purpose or Objective Hypofractionated radical radiotherapy is gaining acceptance with proven non-inferiority demonstrated in breast and prostate cancer. Rotational IMRT with daily image guidance has increased confidence in the safe delivery of hypofractionated treatment. The purpose of this study was to compare efficacy outcomes at a minimum follow up of 2 years in two historic cohorts of locally advanced oropharyngeal carcinoma patients treated with 4-week (20#) or 5-7 week (25-35#) schedule Between June 2009 and May 2012 (4 week cohort), patients undergoing chemoIMRT were treated with 55Gy/20# over 25 days, with synchronous carboplatin. From June 2012 to April 2014 (>4 week cohort), similar patients were treated with either (a) 64Gy/25# over 32 days, (b) 65Gy/30# over 39 days, or (c) 70Gy/35# over 46 days, with synchronous cisplatin or carboplatin. Patients treated with synchronous cetuximab were excluded from this study. Overall survival, local control, distant control, and freedom from recurrence at 2 years were calculated for these cohorts. The effect of the following variables on outcome was analysed: age, T- stage, N-stage, p16 status, smoking status, chemotherapy agent (cisplatin/carboplatin), use of neoadjuvant chemotherapy, and radiotherapy schedule (4-week vs. >4 131 patients with non-metastatic oropharyngeal carcinoma received radical IMRT with concurrent platinum (4-week, n=70; >4 week, n=61). There were significantly more smokers with >10 pack year history (p<0.001) and less patients who received neoadjuvant chemotherapy in the >4 week cohort (p=0.001). Conversely more patients received cisplatin synchronously in this cohort (p<0.001). There were no other significant differences in baseline characteristics. T stage was found to have a statistically significant effect on overall survival (p=0.02) and local control (p=0.04). p16 status was statistically significantly associated with overall survival (p=0.002). None of the other variables evaluated had a statistically significant impact on the endpoints considered. At 2 years, local control (p=0.256), freedom from recurrence (p=0.192), and overall survival (p=0.511) were not statistically different between the 4-week and >4 week cohorts. Conclusion Survival and disease control were comparable in oropharyngeal carcinoma patients treated with 4-week or >4 week hypofractionation schedules. However, due to obvious confounding factors in this retrospective study; accelerated hypofractionated schedules for radical chemoIMRT in oropharyngeal carcinoma need prospective evaluation to determine whether such potentially in a single institution. Material and Methods week). Results

PO-080 Challenges and opportunities in head and neck cancer research in the UK: a survey of oncologists B. Foran 1 , J. Fenwick 2 , B. Byrne 2 , J. Christian 3 1 Weston Park Hospital, Oncology, Sheffield, United Kingdom 2 Merck Serono Ltd- UK- an affiliate of Merck KGaA- Darmstadt- Germany, Medical Affairs, Feltham, United Kingdom 3 Nottingham City Hospital, Oncology, Nottingham, United Kingdom Purpose or Objective Research into head and neck cancer (H&NC) management is vital for the development of new treatment options and improving patient outcomes; recent evidence (Wuthrick et al, 2015) suggests that outcomes are better when patients are treated at centres with high levels of participation in H&NC clinical trials. We conducted a survey of H&N cancer clinicians from oncology departments in the UK and Ireland to gain insights into their experiences of H&NC research. Material and Methods During March 2016, 55 H&N cancer clinicians from centres across the UK and Ireland were invited to complete an e- mail survey about their level of participation in H&NC research, the current challenges and priorities for future research. Here we present the responses of 45 consultants (43 clinical oncologists and 2 surgeons) from National Health Service centres in the UK (excluding Ireland). Results When asked to estimate the amount of Supporting Professional Activities (SPA) time in their weekly job plan for H&NC research, 37% of respondents (13/35 for whom the question was relevant) answered that they had no allocated time. Among the remaining 22 respondents, the median estimated SPA time was 1.25 hours per week (range 0.25-15) ( figure 1 ). 16% of respondents (7/45) are not currently recruiting to a major national clinical trial (De-ESCALaTE, PATHOS, NIMRAD, CompARE, HOPON or DAHANCA 21), 52% (23/44) are not recruiting to any local/non-portfolio trials and 58% (25/43) are not aware of the trials that are open in other centres. The most frequently identified constraints in H&NC research were lack of clinician time and service pressures (80%, 36/45); lack of resources, staff or infrastructure to support and run trials (71%, 32/45); lack of interest (16%, 7/45); patient factors including the relative rarity of H&NC, co- morbidities and poor performance status (13%, 6/45); lack of funding/budget (13%, 6/45) and a lack of H&NC trials (13%, 6/45). A wide variety of priorities and potential questions for future H&NC research were identified.